Showing 1682 results
-
Press release /New FREEDOMS/FREEDOMS II sub-group analysis showed Gilenya-treated patients were six-times more likely to achieve 'no evidence of disease activity (NEDA4)' vs placebo NEDA4 is based on four…
-
Press release /Filings are supported by Phase III ASCLEPIOS I and II studies, where ofatumumab showed highly significant and clinically meaningful reduction in the number of confirmed relapses, evaluated as…
-
Press release /Patients with episodic migraine taking erenumab reported significant and meaningful benefits over six months, with reduced migraine days and acute medication use Fifty percent of patients…
-
Press release /Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical…
-
Press release /The unique optical design of the ACTIVEFOCUS(TM) toric IOL gives astigmatic cataract patients quality distance vision and an increased range of vision to potentially reduce dependence on glasses…
-
Press release /Rapid and profound depletion of B-cells contributed to a halt in disease activity in RMS patients1 A post hoc analysis showed 47.0% and 87.8% of patients treated with ofatumumab achieved no…
-
Featured News /
A new AI-enabled disease management tool in China aims to improve the lives of millions of patients with heart failure.
-
Press release /Pivotal results for efficacy and safety of Cosentyx® (secukinumab) in hidradenitis suppurativa from Phase III SUNSHINE and SUNRISE trials to be debuted as late-breaker at European Academy of…
-
Pulse Update /
-
Featured News /